Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level.

ankylosing spondylitis and related spondyloarthropathies. Rheum Dis Clin North Am 1995;21:117–28. 2. D’Agostino MA, Breban M, Said-Nahal R, Dougados M. Refractory inflammatory heel pain in spondylarthropathy: a significant response to infliximab documented by ultrasound. Arthritis Rheum 2002;46:840–1. 3. Olivieri I, Padula A, Barozzi L. The enthesiopathy: clinical manifestations, imaging and treatment. Bailliére’s Clin Rheumatol 1998;4:665–81. 4. Braun J, Sieper J. Refractory inflammatory heel pain in spondylarthropathy: a significant response to infliximab documented by ultrasound. Reply. Arthritis Rheum 2002;46:841–2. 5. Marzo-Hortega H, McGonagle D, O’Connor P, Emery P. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondyloarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum 2001;44:2112–7. 6. Braun J, Brandt J, Listing J et al. Treatment of active ankylosing spondylitis with infliximnab: a randomised controlled multicentre trial. Lancet 2002;359:1187–93. 7. Haibel H, Brandt HC, Rudwaleit M et al. Efficacy and safety of adalimumab in the treatment of active ankylosing spondylitis: preliminary results of an open-label, 20-week trial. Arthritis Rheum 2004;50(Suppl):S217.